이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ProPhase Labs 미래 성장

Future 기준 확인 2/6

ProPhase Labs은 연간 수입과 매출이 각각 97.4%와 60.9% 증가할 것으로 예상되고 EPS는 연간 105.1%만큼 증가할 것으로 예상됩니다.

주요 정보

69.9%

수익 성장률

37.6%

EPS 성장률

Pharmaceuticals 수익 성장	23.6%
매출 성장률	73.1%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	27 Aug 2024

최근 미래 성장 업데이트

Recent updates

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Jul 03

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12

수익 및 매출 성장 예측

NasdaqCM:PRPH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	95	6	N/A	N/A	1
12/31/2025	50	-16	N/A	N/A	1
12/31/2024	15	-24	N/A	N/A	1
6/30/2024	18	-26	-18	-15	N/A
3/31/2024	29	-24	-21	-17	N/A
12/31/2023	44	-17	-15	-11	N/A
9/30/2023	63	-10	-14	-10	N/A
6/30/2023	79	-4	-6	-3	N/A
3/31/2023	94	7	5	9	N/A
12/31/2022	123	18	25	29	N/A
9/30/2022	146	31	21	23	N/A
6/30/2022	131	27	13	15	N/A
3/31/2022	111	18	13	15	N/A
12/31/2021	79	6	-18	-14	N/A
9/30/2021	39	-5	-21	-16	N/A
6/30/2021	33	-2	-16	-11	N/A
3/31/2021	28	0	-16	-11	N/A
12/31/2020	15	-2	-4	-3	N/A
9/30/2020	12	-2	3	4	N/A
6/30/2020	11	-2	3	3	N/A
3/31/2020	9	-3	-2	-2	N/A
12/31/2019	10	-3	-1	-1	N/A
9/30/2019	11	-3	-1	-1	N/A
6/30/2019	11	-4	-2	-2	N/A
3/31/2019	12	-3	-1	-1	N/A
12/31/2018	13	-2	-2	-2	N/A
9/30/2018	13	-1	-3	-3	N/A
6/30/2018	14	-1	-2	-2	N/A
3/31/2018	13	-1	N/A	-6	N/A
12/31/2017	10	-2	N/A	-3	N/A
9/30/2017	6	-3	N/A	-1	N/A
6/30/2017	5	-3	N/A	-1	N/A
3/31/2017	4	-3	N/A	2	N/A
12/31/2016	4	-4	N/A	0	N/A
9/30/2016	-6	-3	N/A	-2	N/A
6/30/2016	-3	-2	N/A	-4	N/A
3/31/2016	-2	-2	N/A	-5	N/A
12/31/2015	3	-2	N/A	-3	N/A
9/30/2015	21	-3	N/A	-4	N/A
6/30/2015	22	-7	N/A	-3	N/A
3/31/2015	22	-8	N/A	-4	N/A
12/31/2014	22	-8	N/A	-3	N/A
9/30/2014	23	-7	N/A	-1	N/A
6/30/2014	24	-2	N/A	-1	N/A
3/31/2014	24	-1	N/A	0	N/A
12/31/2013	25	0	N/A	1	N/A
9/30/2013	25	0	N/A	-2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PRPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PRPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PRPH 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PRPH 의 수익(연간 60.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: PRPH 의 수익(연간 60.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PRPH 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

ProPhase Labs 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 7.5% to US$18.50

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 19%

Price target increased by 13% to US$17.00

Consensus forecasts updated

Recent updates

ProPhase Labs Receives Non-Compliance Notice from Nasdaq Regarding Listing Rule 5605(c)(2)(A)

ProPhase Labs, Inc. announced delayed 10-Q filing

ProPhase Labs, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Market Cool On ProPhase Labs, Inc.'s (NASDAQ:PRPH) Revenues Pushing Shares 26% Lower

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Price target increased to US$14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insufficient new directors

Chairman & CEO exercised options and sold US$1.8m worth of stock

Investor sentiment improved over the past week

Price target decreased to US$13.00

Upcoming dividend of US$0.30 per share

ProPhase Labs: A Stellar Quarter And Another Special Dividend